

# Felix Beuschlein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1353718/publications.pdf>

Version: 2024-02-01

352  
papers

21,636  
citations

7561

77  
h-index

13758

129  
g-index

364  
all docs

364  
docs citations

364  
times ranked

14508  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2189-2197.	13.9	692
2	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. <i>Cancer</i> , 2009, 115, 243-250.	2.0	597
3	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 689-699.	5.5	595
4	Evidence for two types of brown adipose tissue in humans. <i>Nature Medicine</i> , 2013, 19, 631-634.	15.2	563
5	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	9.4	560
6	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	7.7	532
7	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	7.7	482
8	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. <i>Nature Genetics</i> , 2013, 45, 440-444.	9.4	460
9	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. <i>Nature Genetics</i> , 2015, 47, 31-38.	9.4	450
10	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. <i>New England Journal of Medicine</i> , 2014, 370, 1019-1028.	13.9	355
11	High Incidence of Adrenal Crisis in Educated Patients With Chronic Adrenal Insufficiency: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 407-416.	1.8	308
12	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2012, 18, 2828-2837.	3.2	277
13	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 841-849.	1.8	274
14	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2014, 64, 354-361.	1.3	248
15	Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism. <i>Hypertension</i> , 2012, 59, 592-598.	1.3	246
16	Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn's Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1125-1130.	1.8	237
17	Observational Study Mortality in Treated Primary Aldosteronism. <i>Hypertension</i> , 2012, 60, 618-624.	1.3	235
18	Adrenal Venous Sampling. <i>Hypertension</i> , 2011, 57, 990-995.	1.3	208

#	ARTICLE	IF	CITATIONS
19	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E161-E171.	1.8	196
20	Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. <i>Annals of Oncology</i> , 2015, 26, 2119-2125.	0.6	196
21	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017, 2, .	2.3	187
22	<i>KCNJ5</i> Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. <i>Hypertension</i> , 2012, 59, 235-240.	1.3	176
23	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	2.9	176
24	Frequent incidental discovery of pheochromocytoma: data from a German cohort of 201 pheochromocytoma. <i>European Journal of Endocrinology</i> , 2009, 161, 355-361.	1.9	174
25	Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 869-875.	1.8	166
26	Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3939-3948.	1.8	163
27	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E997-E1004.	1.8	163
28	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 786-798.	5.5	155
29	High Prevalence of Reduced Fecundity in Men with Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1665-1670.	1.8	151
30	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2014, 63, 188-195.	1.3	151
31	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1919-1928.	0.3	151
32	Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4925-4932.	1.8	150
33	Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps. <i>Clinical Chemistry</i> , 2006, 52, 1749-1755.	1.5	136
34	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 181-191.	1.8	132
35	<i>ARMC5</i> Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E926-E935.	1.8	132
36	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5 $\alpha$ -Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 161-171.	1.8	131

#	ARTICLE	IF	CITATIONS
37	The ACE-2 in COVID-19: Foe or Friend?. <i>Hormone and Metabolic Research</i> , 2020, 52, 257-263.	0.7	130
38	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 773-781.	5.5	129
39	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2016, 67, 139-145.	1.3	127
40	International Histopathology Consensus for Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 42-54.	1.8	127
41	Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239.	8.9	127
42	Mass Spectrometry-Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. <i>Clinical Chemistry</i> , 2016, 62, 514-524.	1.5	123
43	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. <i>Clinical Chemistry</i> , 2018, 64, 1646-1656.	1.5	121
44	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1122-1132.	1.8	120
45	Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. <i>European Journal of Endocrinology</i> , 2015, 173, 665-675.	1.9	115
46	Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2012, 167, 35-42.	1.9	111
47	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3903-3911.	1.8	111
48	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1686-1695.	1.8	105
49	Thyroid Hormone Replacement for Central Hypothyroidism: A Randomized Controlled Trial Comparing Two Doses of Thyroxine (T4) with a Combination of T4 and Triiodothyronine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4115-4122.	1.8	104
50	Subclinical hypercortisolism: a state, a syndrome, or a disease?. <i>European Journal of Endocrinology</i> , 2015, 173, M61-M71.	1.9	104
51	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	1.8	103
52	Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 147-155.	0.8	99
53	Adrenal Function After Adrenalectomy for Subclinical Hypercortisolism and Cushing's Syndrome: A Systematic Review of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2637-2645.	1.8	99
54	Biochemical diagnosis of pheochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. <i>Clinical Endocrinology</i> , 2014, 80, 478-486.	1.2	96

#	ARTICLE	IF	CITATIONS
55	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 312-318.	1.8	96
56	Age Below 40 or a Recently Proposed Clinical Prediction Score Cannot Bypass Adrenal Venous Sampling in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1035-E1039.	1.8	95
57	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 641-649.	1.3	94
58	Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. <i>European Journal of Endocrinology</i> , 2011, 165, 301-306.	1.9	93
59	Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. <i>European Journal of Endocrinology</i> , 2012, 167, 7-15.	1.9	92
60	Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2093-E2100.	1.8	92
61	Adrenocortical carcinoma "towards genomics guided clinical care. <i>Nature Reviews Endocrinology</i> , 2019, 15, 548-560.	4.3	92
62	Is Primary Aldosteronism Associated with Diabetes Mellitus? Results of the German Conn's Registry. <i>Hormone and Metabolic Research</i> , 2010, 42, 435-439.	0.7	91
63	Clonal composition of human adrenocortical neoplasms. <i>Cancer Research</i> , 1994, 54, 4927-32.	0.4	91
64	ACTH-receptor expression, regulation and role in adrenocortical tumor formation. <i>European Journal of Endocrinology</i> , 2001, 144, 199-206.	1.9	90
65	Deletion of the Adrenocorticotropin Receptor Gene in Human Adrenocortical Tumors: Implications for Tumorigenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3054-3058.	1.8	89
66	[123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2358-2365.	1.8	88
67	Steroidogenic Factor-1 Is Essential for Compensatory Adrenal Growth Following Unilateral Adrenalectomy. <i>Endocrinology</i> , 2002, 143, 3122-3135.	1.4	84
68	Life-threatening events in patients with pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 173, 757-764.	1.9	84
69	Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. <i>European Journal of Endocrinology</i> , 2014, 171, 209-215.	1.9	83
70	Ectopic pro-opiomelanocortin syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2002, 31, 191-234.	1.2	82
71	Growth analysis of the mouse adrenal gland from weaning to adulthood: time- and gender-dependent alterations of cell size and number in the cortical compartment. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E139-E146.	1.8	82
72	Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. <i>Clinica Chimica Acta</i> , 2013, 418, 50-58.	0.5	82

#	ARTICLE	IF	CITATIONS
73	Neuroendocrine Tumor Recurrence: Diagnosis with <sup>68</sup> Ga-DOTATATE PET/CT. <i>Radiology</i> , 2014, 270, 517-525.	3.6	82
74	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2017, 177, 103-113.	1.9	82
75	Adrenal 20 $\alpha$ -Hydroxysteroid Dehydrogenase in the Mouse Catabolizes Progesterone and 11-Deoxycorticosterone and Is Restricted to the X-Zone. <i>Endocrinology</i> , 2007, 148, 976-988.	1.4	80
76	Total Adrenal Volume But Not Testicular Adrenal Rest Tumor Volume Is Associated with Hormonal Control in Patients with 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2065-2072.	1.8	80
77	Aldosterone Excess Impairs First Phase Insulin Secretion in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2513-2520.	1.8	80
78	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 221-230.	5.5	78
79	Acromegaly Caused by Secretion of Growth Hormone by a Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2000, 342, 1871-1876.	13.9	77
80	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018, 71, 317-325.	1.3	77
81	Interaction Between Dax-1 and Steroidogenic Factor-1 in Vivo: Increased Adrenal Responsiveness to ACTH in the Absence of Dax-1. <i>Endocrinology</i> , 2002, 143, 665-673.	1.4	76
82	Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2011, 12, 43-48.	2.6	75
83	A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, M23-M32.	1.9	74
84	Discerning malignancy in adrenocortical tumors: are molecular markers useful?. <i>European Journal of Endocrinology</i> , 2001, 145, 335-341.	1.9	73
85	High diagnostic accuracy of adrenal core biopsy: Results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. <i>Human Pathology</i> , 2003, 34, 180-186.	1.1	73
86	Prolonged Zona Glomerulosa Insufficiency Causing Hyperkalemia in Primary Aldosteronism after Adrenalectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3965-3973.	1.8	73
87	Activin Induces x-Zone Apoptosis That Inhibits Luteinizing Hormone-Dependent Adrenocortical Tumor Formation in Inhibin-Deficient Mice. <i>Molecular and Cellular Biology</i> , 2003, 23, 3951-3964.	1.1	72
88	Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3192-3202.	1.8	72
89	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. <i>Clinical Chemistry</i> , 2018, 64, 586-596.	1.5	70
90	Major Role of Cathepsin L for Producing the Peptide Hormones ACTH, $\beta$ -Endorphin, and $\beta$ -MSH, Illustrated by Protease Gene Knockout and Expression. <i>Journal of Biological Chemistry</i> , 2008, 283, 35652-35659.	1.6	69

#	ARTICLE	IF	CITATIONS
91	Testicular Adrenal Rest Tumors Develop Independently of Long-Term Disease Control: A Longitudinal Analysis of 50 Adult Men With Congenital Adrenal Hyperplasia due to Classic 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1820-E1826.	1.8	69
92	Screening for membrane hormone receptor expression in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2009, 160, 443-451.	1.9	68
93	Peroxisome Proliferator-Activated Receptor- $\beta$ Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3886-3896.	1.8	67
94	Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. <i>Clinical Endocrinology</i> , 1997, 46, 619-626.	1.2	65
95	Time to Recovery of Adrenal Function After Curative Surgery for Cushing's Syndrome Depends on Etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1300-1308.	1.8	65
96	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3526-3538.	1.8	65
97	Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. <i>European Journal of Endocrinology</i> , 2004, 150, 329-337.	1.9	64
98	PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit. <i>Nature Communications</i> , 2014, 5, 5680.	5.8	63
99	PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588.	1.2	63
100	Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 26-35.	1.3	62
101	Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. <i>European Journal of Endocrinology</i> , 2006, 154, 865-873.	1.9	61
102	Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency. <i>Clinical Endocrinology</i> , 2011, 74, 166-173.	1.2	61
103	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. <i>Genetics in Medicine</i> , 2019, 21, 705-717.	1.1	60
104	Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2013, 168, 75-81.	1.9	58
105	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. <i>European Journal of Endocrinology</i> , 2019, 181, 409-420.	1.9	58
106	Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. <i>Oncotarget</i> , 2016, 7, 79292-79304.	0.8	58
107	Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. <i>European Journal of Endocrinology</i> , 2017, 176, 737-746.	1.9	57
108	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1440.	3.4	57

#	ARTICLE	IF	CITATIONS
109	An Update on Addison's Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 165-175.	0.6	57
110	Pharmacology and Pathophysiology of Mutated KCNJ5 Found in Adrenal Aldosterone-Producing Adenomas. <i>Endocrinology</i> , 2014, 155, 1353-1362.	1.4	56
111	Cellular Pathophysiology of an Adrenal Adenoma-Associated Mutant of the Plasma Membrane Ca <sup>2+</sup> -ATPase ATP2B3. <i>Endocrinology</i> , 2016, 157, 2489-2499.	1.4	54
112	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. <i>Theranostics</i> , 2019, 9, 4946-4958.	4.6	54
113	Characterization of an Adrenocorticotropin (ACTH) Receptor Promoter Polymorphism Leading to Decreased Adrenal Responsiveness to ACTH. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3131-3137.	1.8	53
114	Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. <i>Molecular Psychiatry</i> , 2010, 15, 426-441.	4.1	53
115	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 3020-3030.	3.2	53
116	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. <i>JAMA Network Open</i> , 2020, 3, e2016209.	2.8	53
117	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. <i>Annals of Internal Medicine</i> , 2022, 175, 325-334.	2.0	53
118	Association of plasma aldosterone with the metabolic syndrome in two German populations. <i>European Journal of Endocrinology</i> , 2011, 164, 751-758.	1.9	51
119	Contemporary microsurgical concept for the treatment of Cushing's disease: endocrine outcome in 83 consecutive patients. <i>Clinical Endocrinology</i> , 2012, 76, 560-567.	1.2	51
120	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 650-657.	1.3	51
121	ACTH-Dependent Regulation of MicroRNA As Endogenous Modulators of Glucocorticoid Receptor Expression in the Adrenal Gland. <i>Endocrinology</i> , 2012, 153, 212-222.	1.4	50
122	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. <i>Clinica Chimica Acta</i> , 2019, 490, 46-54.	0.5	50
123	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2985-2993.	1.8	49
124	Timelines in the management of adrenal crisis – targets, limits and reality. <i>Clinical Endocrinology</i> , 2015, 82, 497-502.	1.2	48
125	Pre-B-Cell Transcription Factor 1 and Steroidogenic Factor 1 Synergistically Regulate Adrenocortical Growth and Steroidogenesis. <i>Endocrinology</i> , 2007, 148, 693-704.	1.4	47
126	Side Population Does Not Define Stem Cell-Like Cancer Cells in the Adrenocortical Carcinoma Cell Line NCI h295R. <i>Endocrinology</i> , 2008, 149, 1314-1322.	1.4	47



#	ARTICLE	IF	CITATIONS
127	Quality of life in patients with primary aldosteronism: Gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. <i>Journal of Psychiatric Research</i> , 2012, 46, 1650-1654.	1.5	47
128	Adrenal Cortical Insufficiency. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2013, 110, 882-8.	0.6	47
129	Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4543-4552.	1.8	47
130	The Diagnosis and Treatment of Primary Hyperaldosteronism in Germany. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2009, 106, 305-11.	0.6	47
131	Steroid 21-Hydroxylase Mutations and 21-Hydroxylase Messenger Ribonucleic Acid Expression in Human Adrenocortical Tumors1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2585-2588.	1.8	46
132	SF-1, DAX-1, AND ACD: MOLECULAR DETERMINANTS OF ADRENOCORTICAL GROWTH AND STEROIDOGENESIS. <i>Endocrine Research</i> , 2002, 28, 597-607.	0.6	46
133	Toward a Diagnostic Score in Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 766.	1.5	46
134	COVID-19 targets human adrenal glands. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 13-16.	5.5	46
135	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e307-e318.	1.8	45
136	Silencing Mutated $\beta$ -Catenin Inhibits Cell Proliferation and Stimulates Apoptosis in the Adrenocortical Cancer Cell Line H295R. <i>PLoS ONE</i> , 2013, 8, e55743.	1.1	45
137	Bone Morphogenetic Proteins 2 and 5 Are Down-regulated in Adrenocortical Carcinoma and Modulate Adrenal Cell Proliferation and Steroidogenesis. <i>Cancer Research</i> , 2009, 69, 5784-5792.	0.4	44
138	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3205.	1.8	44
139	Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2010, 107, 885-91.	0.6	44
140	AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4366-4370.	1.8	43
141	PRKACA Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3010-3017.	1.8	43
142	DAX-1 Expression in Human Adrenocortical Neoplasms: Implications for Steroidogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2597-2600.	1.8	42
143	A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum. <i>Journal of Endocrinology</i> , 2008, 196, 215-224.	1.2	42
144	H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1376-E1380.	1.8	42

#	ARTICLE	IF	CITATIONS
145	Frequency and Clinical Correlates of Somatic Ying Yang 1 Mutations in Sporadic Insulinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E776-E782.	1.8	42
146	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	4.7	42
147	Steroid 21-Hydroxylase Mutations and 21-Hydroxylase Messenger Ribonucleic Acid Expression in Human Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2585-2588.	1.8	42
148	Localization and expression of adrenocorticotrophic hormone receptor mRNA in normal and neoplastic human adrenal cortex. <i>Journal of Endocrinology</i> , 1998, 156, 415-423.	1.2	41
149	Presence of Brown Adipocytes in Retroperitoneal Fat From Patients With Benign Adrenal Tumors: Relationship With Outdoor Temperature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4097-4104.	1.8	41
150	EJE Prize 2013: Regulation of aldosterone secretion: from physiology to disease. <i>European Journal of Endocrinology</i> , 2013, 168, R85-R93.	1.9	41
151	Linear and Volumetric Evaluation of the Adrenal Gland—MDCT-Based Measurements of the Adrenals. <i>Academic Radiology</i> , 2014, 21, 1465-1474.	1.3	41
152	Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. <i>Clinical Endocrinology</i> , 2001, 54, 627-632.	1.2	37
153	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5658-5664.	1.8	37
154	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. <i>European Journal of Endocrinology</i> , 2018, 178, 57-63.	1.9	37
155	Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18493-18498.	3.3	36
156	Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of $\beta$ -catenin in adrenocortical carcinoma. <i>Oncogenesis</i> , 2015, 4, e161-e161.	2.1	36
157	CBP/p300-Interacting Transactivator, with Glu/Asp-Rich C-Terminal Domain, 2, and Pre-B-Cell Leukemia Transcription Factor 1 in Human Adrenal Development and Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 678-683.	1.8	35
158	A High Aldosterone to Renin Ratio Is Associated With High Serum Parathyroid Hormone Concentrations in the General Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 965-971.	1.8	35
159	Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal Cushing Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4331-4340.	1.8	35
160	The role of regulated necrosis in endocrine diseases. <i>Nature Reviews Endocrinology</i> , 2021, 17, 497-510.	4.3	35
161	Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonadal marker genes. <i>Journal of Endocrinology</i> , 2006, 190, 47-57.	1.2	34
162	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3295-3307.	1.8	34

#	ARTICLE	IF	CITATIONS
163	ACTH after 15 min distinguishes between Cushing's disease and ectopic Cushing's syndrome: a proposal for a short and simple CRH test. <i>European Journal of Endocrinology</i> , 2015, 173, 197-204.	1.9	33
164	The SPARTACUS Trial: Controversies and Unresolved Issues. <i>Hormone and Metabolic Research</i> , 2017, 49, 936-942.	0.7	33
165	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	1.8	33
166	Consequences of the COVID-19 pandemic for patients with metabolic diseases. <i>Nature Metabolism</i> , 2021, 3, 289-292.	5.1	33
167	HIF2 $\alpha$ supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640.	1.6	33
168	cAMP signaling in cortisol-producing adrenal adenoma. <i>European Journal of Endocrinology</i> , 2015, 173, M99-M106.	1.9	32
169	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 353-363.	1.4	32
170	The Prevalence of Familial Hyperaldosteronism in Apparently Sporadic Primary Aldosteronism in Germany: a Single Center Experience. <i>Hormone and Metabolic Research</i> , 2012, 44, 215-220.	0.7	31
171	$\beta$ -Catenin and FGFR2 regulate postnatal rosette-based adrenocortical morphogenesis. <i>Nature Communications</i> , 2020, 11, 1680.	5.8	31
172	Expression and spatio-temporal distribution of differentiation and proliferation markers during mouse adrenal development. <i>Gene Expression Patterns</i> , 2007, 7, 72-81.	0.3	30
173	Animal models of adrenocortical tumorigenesis. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 78-86.	1.6	30
174	Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2853-e2863.	1.8	30
175	Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1-28 to Pomc <sup>-/-</sup> mice reduces food intake and weight but does not affect adrenal growth or corticosterone production. <i>Journal of Endocrinology</i> , 2006, 190, 515-525.	1.2	29
176	Links between aldosterone excess and metabolic complications: A comprehensive review. <i>Diabetes and Metabolism</i> , 2020, 46, 1-7.	1.4	29
177	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e282-e289.	1.8	29
178	Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4490-e4498.	1.8	29
179	Intraoperative haemodynamic stability in patients with pheochromocytoma ? minimally invasive vs conventional open surgery. <i>Clinical Endocrinology</i> , 2006, 65, 352-358.	1.2	28
180	Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. <i>International Journal of Oncology</i> , 2013, 43, 1824-1832.	1.4	28

#	ARTICLE	IF	CITATIONS
181	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 274-282.	1.2	28
182	Molecular adrenocortical tumourigenesis. <i>European Journal of Clinical Investigation</i> , 2000, 30, 63-68.	1.7	27
183	Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 809-816.	1.3	27
184	In situ metabolomics of aldosterone-producing adenomas. <i>JCI Insight</i> , 2019, 4, .	2.3	27
185	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2027-e2036.	1.8	27
186	Steroidogenic acute regulatory protein mRNA expression in adrenal tumours. <i>European Journal of Endocrinology</i> , 2000, 142, 294-299.	1.9	26
187	Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 38-46.	0.8	26
188	Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2015, 172, 443-450.	1.9	26
189	Cushing's syndrome: a model for sarcopenic obesity. <i>Endocrine</i> , 2017, 57, 481-485.	1.1	26
190	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. <i>European Journal of Endocrinology</i> , 2018, 178, 605-611.	1.9	26
191	Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. <i>Journal of Medical Genetics</i> , 2022, 59, 287-293.	1.5	26
192	Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry. <i>Clinical Endocrinology</i> , 2012, 76, 473-477.	1.2	25
193	Adrenal Venous Sampling-Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1400-e1407.	1.8	25
194	ACTH 1-24 inhibits proliferation of adrenocortical tumors in vivo. <i>European Journal of Endocrinology</i> , 2005, 153, 435-444.	1.9	24
195	MANAGEMENT OF ENDOCRINE DISEASE: Fertility, pregnancy and lactation in women with adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2018, 178, R45-R53.	1.9	24
196	Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up. <i>European Journal of Endocrinology</i> , 2018, 179, 109-116.	1.9	24
197	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	1.4	24
198	Performance of LC-MS/MS and immunoassay based 24-h urine free cortisol in the diagnosis of Cushing's syndrome. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 190, 193-197.	1.2	24

#	ARTICLE	IF	CITATIONS
199	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4459-e4473.	1.8	24
200	Interaction Between Dax-1 and Steroidogenic Factor-1 in Vivo: Increased Adrenal Responsiveness to ACTH in the Absence of Dax-1. <i>Endocrinology</i> , 2002, 143, 665-673.	1.4	24
201	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2017, 177, 227-237.	1.9	23
202	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. <i>Cancers</i> , 2019, 11, 809.	1.7	23
203	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in pheochromocytomas and paragangliomas. <i>Journal of Pathology</i> , 2020, 251, 378-387.	2.1	23
204	Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. <i>European Journal of Endocrinology</i> , 2013, 169, 657-663.	1.9	22
205	Worsening of lipid metabolism after successful treatment of primary aldosteronism. <i>Endocrine</i> , 2016, 54, 198-205.	1.1	22
206	Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. <i>Endocrine</i> , 2017, 58, 503-512.	1.1	22
207	Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 326-333.	1.7	22
208	Role of the Inhibin/Activin System and Luteinizing Hormone in Adrenocortical Tumorigenesis. <i>Hormone and Metabolic Research</i> , 2004, 36, 392-396.	0.7	21
209	Characterization of NCI-H295R Cells as an In Vitro Model of Hyperaldosteronism. <i>Hormone and Metabolic Research</i> , 2013, 45, 124-129.	0.7	21
210	Diastrophic Dysplasia Sulfate Transporter (SLC26A2) Is Expressed in the Adrenal Cortex and Regulates Aldosterone Secretion. <i>Hypertension</i> , 2014, 63, 1102-1109.	1.3	21
211	Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. <i>Endocrine-Related Cancer</i> , 2014, 21, 383-394.	1.6	21
212	Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2018, 143, 199-211.	2.3	21
213	Metabolic Alterations in Patients with Pheochromocytoma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 129-136.	0.6	21
214	Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease?. <i>Molecular Psychiatry</i> , 2019, 24, 2-9.	4.1	21
215	Genetic influence of an ACTH receptor promoter polymorphism on adrenal androgen secretion. <i>European Journal of Endocrinology</i> , 2005, 153, 711-715.	1.9	20
216	Evaluation of a Standardized Protocol for Processing Adrenal Tumor Samples: Preparation for a European Adrenal Tumor Bank. <i>Hormone and Metabolic Research</i> , 2010, 42, 93-101.	0.7	20

#	ARTICLE	IF	CITATIONS
217	A microsphere-based duplex competitive immunoassay for the simultaneous measurements of aldosterone and testosterone in small sample volumes: Validation in human and mouse plasma. <i>Steroids</i> , 2010, 75, 1089-1096.	0.8	20
218	Therapeutic options after surgical failure in Cushing's disease: A critical review. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101270.	2.2	20
219	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression – Lessons from primary aldosteronism. <i>Journal of Psychiatric Research</i> , 2020, 130, 82-88.	1.5	20
220	The Effect of Biochemical Remission on Bone Metabolism in Cushing's Syndrome: A 2-Year Follow-Up Study. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1711-1717.	3.1	20
221	Tumor Size of Conn's Adenoma and Comorbidities. <i>Hormone and Metabolic Research</i> , 2009, 41, 785-788.	0.7	19
222	Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma. <i>Journal of Endocrinology</i> , 2012, 213, 155-161.	1.2	19
223	Association between 25-Hydroxyvitamin D Status and Components of Body Composition and Glucose Metabolism in Older Men and Women. <i>Nutrients</i> , 2018, 10, 1826.	1.7	19
224	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3812-3820.	1.8	19
225	Proteomic Landscape of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2019, 73, 469-480.	1.3	19
226	Hypokalemia and the Prevalence of Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2020, 52, 347-356.	0.7	19
227	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1111-e1128.	1.8	19
228	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. <i>European Journal of Endocrinology</i> , 2019, 181, 647-657.	1.9	19
229	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1181-e1192.	1.8	19
230	Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 407-413.	1.1	18
231	Isoenergetic Feeding of Low Carbohydrate-High Fat Diets Does Not Increase Brown Adipose Tissue Thermogenic Capacity in Rats. <i>PLoS ONE</i> , 2012, 7, e38997.	1.1	18
232	KCNJ5 Mutations: Sex, Salt and Selection. <i>Hormone and Metabolic Research</i> , 2015, 47, 953-958.	0.7	18
233	TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors. <i>Molecular and Cellular Endocrinology</i> , 2016, 423, 87-95.	1.6	18
234	The impact of Conn's syndrome - mild cortisol excess in primary aldosteronism drives diabetes risk. <i>Journal of Hypertension</i> , 2017, 35, 2548.	0.3	18

#	ARTICLE	IF	CITATIONS
235	Steroidogenic Factor-1 Is Essential for Compensatory Adrenal Growth Following Unilateral Adrenalectomy. <i>Endocrinology</i> , 2002, 143, 3122-3135.	1.4	18
236	DAX-1 Expression in Human Adrenocortical Neoplasms: Implications for Steroidogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2597-2600.	1.8	18
237	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. <i>European Journal of Endocrinology</i> , 2020, 183, 453-462.	1.9	18
238	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. <i>European Journal of Cancer</i> , 2022, 169, 32-41.	1.3	18
239	Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. <i>European Journal of Endocrinology</i> , 2015, 173, 43-52.	1.9	17
240	Lack of utility of SDHB mutation testing in adrenergic metastatic pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 172, 89-95.	1.9	17
241	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2016, 23, 825-837.	1.6	17
242	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. <i>Scientific Reports</i> , 2017, 7, 49.	1.6	17
243	Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 784-792.	1.3	17
244	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	1.8	17
245	Is there a role for the adrenal glands in long COVID?. <i>Nature Reviews Endocrinology</i> , 2022, 18, 451-452.	4.3	17
246	Steroidogenic Acute Regulatory (StAR)-Directed Immunotherapy Protects against Tumor Growth of StAR-Expressing Sp2-0 Cells in a Rodent Adrenocortical Carcinoma Model. <i>Endocrinology</i> , 2004, 145, 1760-1766.	1.4	16
247	Anti Insulin-Like Growth Factor I Receptor Immunoliposomes: A Single Formulation Combining Two Anticancer Treatments with Enhanced Therapeutic Efficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 943-952.	1.8	16
248	Aldosterone Producing Adrenal Adenomas are Characterized by Activation of Calcium/Calmodulin-dependent Protein Kinase (CaMK) Dependent Pathways. <i>Hormone and Metabolic Research</i> , 2011, 43, 106-111.	0.7	16
249	Advances in adrenal tumors 2018. <i>Endocrine-Related Cancer</i> , 2018, 25, R405-R420.	1.6	16
250	Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. <i>Journal of the Endocrine Society</i> , 2021, 5, A166-A167.	0.1	16
251	Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated <i>in vitro</i> and <i>in vivo</i> "challenges and prospects. <i>Oncotarget</i> , 2015, 6, 43698-43711.	0.8	15
252	Genetics of adrenocortical tumours. <i>Journal of Internal Medicine</i> , 2016, 280, 540-550.	2.7	15

#	ARTICLE	IF	CITATIONS
253	The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism. <i>Journal of Hypertension</i> , 2016, 34, 2066-2073.	0.3	15
254	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2018, 178, 181-188.	1.9	15
255	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 578-584.	0.6	15
256	Oncogenic features of the bone morphogenetic protein 7 (BMP7) in pheochromocytoma. <i>Oncotarget</i> , 2015, 6, 39111-39126.	0.8	15
257	Adrenocortical Tumorigenesis. <i>Annals of the New York Academy of Sciences</i> , 2006, 1088, 319-334.	1.8	14
258	Role of bone morphogenetic proteins in adrenal physiology and disease. <i>Journal of Molecular Endocrinology</i> , 2010, 44, 203-211.	1.1	14
259	Primary Adrenal Lymphoma: 3 Case Reports with Different Outcomes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 208-213.	0.6	14
260	Xenograft models for adrenocortical carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2016, 421, 28-33.	1.6	14
261	Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome. <i>Endocrine-Related Cancer</i> , 2017, 24, L73-L77.	1.6	14
262	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 487.	1.5	14
263	Primary and Secondary Hyperparathyroidism in Patients with Primary Aldosteronism – Findings From the German Connâ€™s Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 246-254.	0.6	14
264	Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2021, 77, 1332-1340.	1.3	14
265	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.	1.1	14
266	Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3723-e3730.	1.8	14
267	Volumetric and densitometric evaluation of the adrenal glands in patients with primary aldosteronism. <i>Clinical Endocrinology</i> , 2017, 86, 325-331.	1.2	13
268	Perioperative Management of Endocrine Active Adrenal Tumors. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 137-146.	0.6	13
269	Endocrine responses during CPAP withdrawal in obstructive sleep apnoea: data from two randomised controlled trials. <i>Thorax</i> , 2019, 74, 1102-1105.	2.7	13
270	Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety. <i>Journal of Psychiatric Research</i> , 2021, 137, 376-382.	1.5	13



#	ARTICLE	IF	CITATIONS
271	Patients with low IGF-I after curative surgery for Cushing's syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. <i>European Journal of Endocrinology</i> , 2021, 184, 813-821.	1.9	13
272	Aged PROP1 Deficient Dwarf Mice Maintain ACTH Production. <i>PLoS ONE</i> , 2011, 6, e28355.	1.1	13
273	Identification of adrenal genes regulated in a potassium-dependent manner. <i>Journal of Molecular Endocrinology</i> , 2010, 45, 193-206.	1.1	12
274	Daily adjustment of glucocorticoids by patients with adrenal insufficiency. <i>Clinical Endocrinology</i> , 2019, 91, 256-262.	1.2	12
275	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. <i>International Journal of Obesity</i> , 2019, 43, 263-275.	1.6	12
276	Patients With Primary Aldosteronism Respond to Unilateral Adrenalectomy With Long-Term Reduction in Salt Intake. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e484-e493.	1.8	12
277	Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101347.	2.2	12
278	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2021, 185, 179-191.	1.9	12
279	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	1.6	12
280	Clinical and molecular evidence for DAX-1 inhibition of steroidogenic factor-1-dependent ACTH receptor gene expression. <i>European Journal of Endocrinology</i> , 2005, 152, 769-776.	1.9	11
281	Gender-, strain-, and inheritance-dependent variation in aldosterone secretion in mice. <i>Journal of Endocrinology</i> , 2012, 215, 375-381.	1.2	11
282	IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2016, 428, 82-88.	1.6	11
283	Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy. <i>Hormone and Metabolic Research</i> , 2017, 49, 208-213.	0.7	11
284	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154297.	1.5	11
285	Circulating microRNA Expression in Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 620012.	1.5	11
286	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. <i>Endocrine Connections</i> , 2018, 7, 1168-1177.	0.8	11
287	The Role of the ACTH Receptor in Adrenal Tumors: Identification of a Novel Microsatellite Marker. <i>Hormone and Metabolic Research</i> , 2004, 36, 406-410.	0.7	10
288	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. <i>Hypertension</i> , 2015, 66, 248-253.	1.3	10

#	ARTICLE	IF	CITATIONS
289	PRKACA Mutations in Adrenal Adenomas: Genotype/Phenotype Correlations. <i>Hormone and Metabolic Research</i> , 2017, 49, 301-306.	0.7	10
290	Adrenal Incidentalomas: Presentation and Clinical Work-Up. <i>Hormone Research in Paediatrics</i> , 2007, 68, 191-194.	0.8	9
291	PBX1 is dispensable for neural commitment of RA-treated murine ES cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2009, 45, 252-263.	0.7	9
292	Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 547-560.	1.6	9
293	Comparative Genomics and Transcriptome Profiling in Primary Aldosteronism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1124.	1.8	9
294	The role of adrenal venous sampling (AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients. <i>Endocrine</i> , 2022, 76, 434-445.	1.1	9
295	The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex – a multicenter-study of 3566 Caucasian and Asian subjects. <i>European Journal of Endocrinology</i> , 2022, 187, 361-372.	1.9	9
296	Regulation of Human MC2-R Gene Expression by CREB, CREM, and ICER in the Adrenocortical Cell Line Y1. <i>Hormone and Metabolic Research</i> , 2007, 39, 560-566.	0.7	8
297	Beyond a Disease Registry: An Integrated Virtual Environment for Adrenal Cancer Research. <i>Journal of Grid Computing</i> , 2016, 14, 515-532.	2.5	8
298	Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells. <i>Cancer Letters</i> , 2017, 406, 54-63.	3.2	8
299	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. <i>Hypertension</i> , 2021, 77, 1647-1658.	1.3	8
300	Novel molecular signatures for adrenocortical carcinoma. <i>Nature Reviews Endocrinology</i> , 2009, 5, 297-299.	4.3	7
301	Utilization of a Mutagenesis Screen to Generate Mouse Models of Hyperaldosteronism. <i>Endocrinology</i> , 2011, 152, 326-331.	1.4	7
302	Sleep quality in patients with primary aldosteronism. <i>Hormones</i> , 2014, 13, 57-64.	0.9	7
303	Treatment of Primary Aldosteronism With mTORC1 Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4703-4714.	1.8	7
304	Identification of glucocorticoid-related molecular signature by whole blood methylome analysis. <i>European Journal of Endocrinology</i> , 2022, 186, 297-308.	1.9	7
305	Decreased p44/42 Mitogen-Activated Protein Kinase Phosphorylation in Gender- or Hormone-Related But Not during Age-Related Adrenal Gland Growth in Mice. <i>Endocrinology</i> , 2009, 150, 1269-1277.	1.4	6
306	The tumor stem cell concept – Implications for endocrine tumors?. <i>Molecular and Cellular Endocrinology</i> , 2009, 300, 158-163.	1.6	6

#	ARTICLE	IF	CITATIONS
307	Mouse models of adrenal tumorigenesis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 865-875.	2.2	6
308	Progress in Primary Aldosteronism: Translation on the Move. <i>Hormone and Metabolic Research</i> , 2015, 47, 933-934.	0.7	6
309	Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy. <i>Scientific Reports</i> , 2021, 11, 11181.	1.6	6
310	Animal Models of Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2010, 42, 446-449.	0.7	5
311	Urocortin-dependent effects on adrenal morphology, growth, and expression of steroidogenic enzymes in vivo. <i>Journal of Molecular Endocrinology</i> , 2012, 48, 159-167.	1.1	5
312	Virilization of a Young Girl Caused by Concomitant Ectopic and Intra-Adrenal Adenomas of the Adrenal Cortex. <i>Hormone Research in Paediatrics</i> , 2013, 79, 318-322.	0.8	5
313	Novel genes in primary aldosteronism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014, 21, 154-158.	1.2	5
314	Adrenal and Ovarian Phenotype of a Tissue-Specific Urocortin 2â€œOverexpressing Mouse Model. <i>Endocrinology</i> , 2015, 156, 2646-2656.	1.4	5
315	Genetic characterization of a mouse line with primary aldosteronism. <i>Journal of Molecular Endocrinology</i> , 2017, 58, 67-78.	1.1	5
316	The Adrenal Gland: Central Relay in Health and Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 81-83.	0.6	5
317	Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion. <i>Discover Oncology</i> , 2021, 12, 9.	0.8	5
318	Cytotoxic T-cell Response against Steroidogenic Acute Regulatory Protein using DNA Vaccination Followed by Vaccinia Virus Infection in a Mouse Adrenal Carcinoma Model. <i>Hormone and Metabolic Research</i> , 2004, 36, 411-414.	0.7	4
319	Mechanistic Roles of Inhibin as a Tumor Suppressor in the Adrenal Cortex. <i>Endocrine Research</i> , 2004, 30, 585-586.	0.6	4
320	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1262-E1269.	1.8	4
321	Somatic PRKACA Mutations: Association With Transition From Pituitary-Dependent to Adrenal-Dependent Cushing Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5651-5657.	1.8	4
322	Effects of chronically high levels of aldosterone on different cognitive dimensions: an investigation in patients with primary aldosteronism. <i>Endocrine Connections</i> , 2019, 8, 407-415.	0.8	4
323	Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. <i>Endocrinology</i> , 2022, 163, .	1.4	4
324	Signs, symptoms and biochemistry in recurrent Cushing disease: a prospective pilot study. <i>Endocrine</i> , 2021, 73, 762-766.	1.1	3

#	ARTICLE	IF	CITATIONS
325	Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2022, 75, 254-265.	1.1	3
326	Clinical Impact of Recent Advances in the Biology of Adrenocortical Cancer. , 2003, 13, 470-478.		2
327	Connshing syndrome““Amyth or reality?. <i>Annales D'Endocrinologie</i> , 2018, 79, 123-124.	0.6	2
328	Sleep-EEG in patients with primary aldosteronism in comparison to healthy controls and patients with depression. <i>Journal of Psychiatric Research</i> , 2019, 112, 52-60.	1.5	2
329	Circular RNA-based biomarkers in blood of patients with Fabry disease and related phenotypes. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2020-107086.	1.5	2
330	Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2021, 5, A70-A70.	0.1	2
331	Somatic RET mutation in a patient with pigmented adrenal pheochromocytoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150117.	0.2	2
332	Endocrine disorders in patients with Fabry disease: insights from a reference centre prospective study. <i>Endocrine</i> , 2022, 75, 728-739.	1.1	2
333	Incidence of Primary Aldosteronism in Patients with Hypokalemia (IPAHK+): Study Design and Baseline Characteristics. <i>Hormone and Metabolic Research</i> , 2021, 53, 787-793.	0.7	2
334	The side population phenomenon enriches for designated adrenocortical progenitor cells in mice. <i>Journal of Endocrinology</i> , 2012, 215, 383-391.	1.2	1
335	Animal Models of Adrenal Genetic Disorders. , 2014, , 323-329.		1
336	Predictive Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. <i>Hormone and Metabolic Research</i> , 2021, 53, 24-31.	0.7	1
337	OR34-02 Somatic Transmembrane Domain Mutations of a Cell Adhesion Molecule, CADM1, Cause Primary Aldosteronism by Preventing Gap Junction Communication Between Adrenocortical Cells. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	1
338	Progress in Primary Aldosteronism 2. <i>Hormone and Metabolic Research</i> , 2012, 44, 155-156.	0.7	0
339	[OP.3A.06] LONG TERM FOLLOW-UP IN PATIENTS OPERATED ON A PHEOCHROMOCYTOMA OR A PARAGANGLIOMA. <i>Journal of Hypertension</i> , 2016, 34, e28.	0.3	0
340	Dopamine agonist-responsive Cushingâ€™s disease. <i>BMJ Case Reports</i> , 2019, 12, bcr-2018-228045.	0.2	0
341	Response to Letter to the Editor: â€œCT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentalomaâ€. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3842-e3843.	1.8	0
342	Calcineurin-NFATc4 Pathway Is Activated Upon K+-stimulation of Adrenal Aldosterone Production. <i>Journal of the Endocrine Society</i> , 2021, 5, A805-A806.	0.1	0

#	ARTICLE	IF	CITATIONS
343	Aldosterone Insufficiency Contributes to Calcineurin Inhibitor-induced Hyperkalemia. FASEB Journal, 2021, 35, .	0.2	0
344	Mouse Models of Adrenal Tumorigenesis. , 2009, , 325-340.		0
345	Diagnosis and Treatment of Primary Aldosteronism in 2017: Did We Achieve Our Goals?. Hormone and Metabolic Research, 2017, 49, 905-907.	0.7	0
346	OR29-2 Mild Autonomous Cortisol Excess (MACE) in Adrenal Incidentalomas - Metabolic Risk Profile and Urinary Steroid Metabolome Analysis in 1208 Prospectively Recruited Patients. Journal of the Endocrine Society, 2019, 3, .	0.1	0
347	SUN-381 Somatic PRKACA Mutations In Patients With Transition From Pituitary-dependent To Adrenal-dependent Cushing's Syndrome. Journal of the Endocrine Society, 2019, 3, .	0.1	0
348	MON-380 Tinnitus with Unexpected Spanish Roots: Head and Neck Paragangliomas Caused by SDHAF2 Mutation. Journal of the Endocrine Society, 2019, 3, .	0.1	0
349	SAT-LB23 Paraneoplastic Hypercalcemia in a PTH Producing Adrenocortical Carcinoma - a Rare and Deadly Condition. Journal of the Endocrine Society, 2020, 4, .	0.1	0
350	OR34-04 Efficiency of Adrenal Venous Sampling in the Treatment Choice of Primary Aldosteronism (AVSTAT Study). Journal of the Endocrine Society, 2020, 4, .	0.1	0
351	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. Journal of the Endocrine Society, 2020, 4, .	0.1	0
352	COVID-19 in Fabry disease: a reference center prospective study. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	0